Information  X 
Enter a valid email address
  Print          More announcements

Wednesday 06 January, 2021

F-star Therapeutics, Inc

F-star Therapeutics to Participate in Upcoming Conferences

F-star Therapeutics to Participate in Upcoming Conferences

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces that members of the management team will be participating in the H.C. Wainwright BioConnect Conference, the LifeSci Advisors 10th Annual Corporate Access Event and the B Riley Oncology Event. All events will take place virtually.

Details for the events are as follows:

H.C. Wainwright BioConnect Conference

Fireside chat with CEO, Eliot Forster
Dates: January 11-14, 2021

LifeSci Advisors 10th Annual Corporate Access Event

1x1 Meetings with Management
Dates: January 6-8, 11-14, 2021

B Riley Oncology Investor Conference

Presentation by CEO, Eliot Forster
Date: January 20, 2021
Time: 11:30am – 12:00pm

Eliot Forster, CEO of F-star Therapeutics, Inc., said: “Having listed on NASDAQ at the end of 2020, we are looking forward to the opportunity to discuss the Company, our pipeline and our most recent progress at these events. We have had numerous updates across our four clinical programs in recent months and continue our dedication to developing next generation immunotherapies to transform the lives of patients with cancer.”

About F-star Therapeutics, Inc.

F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit www.f-star.com.

For further information, please contact:

For investor inquiries
Lindsey Trickett
VP Investor Relations & Communications
+1 240 543 7970
[email protected]

For media inquiries
Next Step Communications
Nigel Smith
+1 781 326 1741
[email protected]



a d v e r t i s e m e n t